International Pharma Talks

Artificial Intelligence is Reshaping Pharmacovigilance – But Are You Ready? With over 1.5 million adverse drug reactions reported annually in the EU alone, the pressure on pharmacovigilance systems has never been greater. Could artificial intelligence (AI) be the answer? In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, discusses how AI is transforming the landscape of drug safety, and what pharmaceutical companies must do to stay ahead. From automation and real-time signal detection to regulatory hurdles and ethical challenges, we break down how AI is redefining the future of pharmacovigilance and what that means for compliance, patient safety, and innovation. You’ll learn more about: * How AI enhances adverse event detection across large, unstructured data sources * Compliance requirements under EMA, FDA, and ISO standards * Why early-stage integration of AI is a strategic (not optional) investment * How companies can adopt scalable, cost-effective AI solutions without compromising compliance The integration of AI into pharmacovigilance isn’t a distant possibility, it’s an urgent priority. But real transformation requires more than just algorithms. It demands strategic planning, regulatory alignment, and expert guidance. Tune in now to understand how your company can use AI to enhance pharmacovigilance performance, reduce risk, and strengthen patient trust. Learn more at els-solutions.com/ [https://www.els-group.org]This episode was recorded in 2025. Some of the data discussed may have changed since then. This podcast has been prepared using various bibliographic sources. The opinions expressed reflect the professional experiences of ELS members and referenced material.

Brazil’s medicinal cannabis market is evolving rapidly, with more patients, new regulatory pathways, and a growing industry presence. But how accessible are these treatments, and what are the biggest challenges companies face? In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins explores the business and regulatory landscape of medicinal cannabis in Brazil. From market trends to future policy changes, we’ll break down what’s shaping this fast-moving sector. You’ll learn more about: * The surge in patient numbers and what it means for market growth * Regulatory frameworks for cannabis-based treatments and their challenges * Why official drug registrations remain rare despite existing pathways * The impact of Anvisa’s upcoming regulatory agenda on the industry With Brazil poised to become a key player in Latin America's cannabis market, understanding these developments is crucial. Tune in now to stay ahead of the curve. Learn more at els-solutions.com [https://els-solutions.com]. "This episode was recorded in 2024. As such, some of the data discussed may have changed. This podcast has been prepared from different bibliographic sources. The opinions and comments conveyed therein are based on previous corporate experiences of ELS members, in addition to the references listed."

The pharmaceutical market is constantly evolving,shaped by innovation, shifting demands, and regulatory developments. In this episode of International Pharma Talks, our host, Dr. Diogo Sousa-Martins explores how the industry is changing and what these transformations mean forthe future. Tune in to discover: *  How technology is reshaping drug development andhealthcare * The impact of regulatory changes on marketstrategies * The shift towards personalized medicine andpatient-centered care * The role of emerging markets in the globalpharmaceutical landscape   Understanding these changes is crucial for staying ahead in the industry. Learn more about it at els-solutions.com   * "This podcast has been prepared from different bibliographic sources. As such, the opinion and comments conveyed therein are based on previous corporate experiences of ELS members, in addition to the referenceslisted."

What does the future look like for the pharma industry in 2025? Join Dr. Diogo Sousa-Martins in our latest episode of International Pharma Talks, where he explores the key trends shaping the pharmaceutical landscape this year. With rapid advancements in AI, regulatory changes, and the growing importance of personalized medicine, staying ahead has never been more critical. In this episode, you’ll learn more about: - The rise of AI in drug discovery and its impact on R&D efficiency - Global market dynamics and the expansion of emerging pharma markets - The growing role of personalized medicine in patient care - Regulatory changes influencing drug approvals and market success and many more.. As the industry evolves, understanding these shifts will be essential for success. Tune in now to gain valuable insights and prepare for what’s ahead. Learn more about it at els-solutions.com * "This podcast has been prepared from different bibliographic sources. As such, the opinion and comments conveyed therein are based on previous corporate experiences of ELS members, in addition to the references listed."

In the 37th episode, our host, Dr. Diogo Sousa-Martins delves into the dynamic and rapidly evolving cannabis market in Europe, analyzing how the regulatory frameworks, market trends, and societal implications works in this controversial yet very promising industry. From the rise of medical cannabis markets in Germany, Poland, the Czech Republic, and Switzerland to recent advancements in recreational cannabis legalization in European countries, this episode sheds light on the shifting landscape of cannabis policies across the continent. Some of the topics this episode will cover: - The role of cannabis in medicinal and recreational markets. - Challenges faced by companies, including regulatory inconsistencies, misinformation, and the need for clinical research. - Insights into the economic potential of cannabis markets, with projections and data on emerging leaders in Europe. Tune in to discover how cannabis regulation and market expansion are shaping the future of medicine, business, and society. For more information regarding regulatory and market expansion issues, visit ⁠els-solutions.com [https://www.els-solutions.com/?utm_source=spotify&utm_medium=channel&utm_campaign=awareness]